| Company Name | Daiichi Sankyo Taiwan |
|---|---|
| Protocol Number | DU176b-C-A4008 |
| Title of Study | Non-interventional study on edoxaban treatment in routine clinical practice for patients with non valvular atrial fibrillation in Korea and Taiwan |
| Primary Objective | The primary objective of this study is to collect and evaluate real-world safety data on bleeding events including intracranial haemorrhage, adverse events such as liver adverse events, cardiovascular (CV) and all-cause mortality in NVAF patients treated with edoxaban up to 2 years with regard to onset (relative to treatment with edoxaban) of the event, duration, severity and outcome. |
| Number of Sites | 10 |
| Period of Study | From：04/06/2017 to：04/05/2021 |
| Number of Patients | 1000人 |
| IRB Approval Date | Dec. 19, 2016 |
| Publication Plan / Date | TBC |
